Free Trial

Stoke Therapeutics (STOK) News Today

Stoke Therapeutics logo
$11.57 -0.09 (-0.77%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$11.85 +0.28 (+2.39%)
As of 06/18/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STOK Latest News

FY2025 EPS Estimates for STOK Reduced by Cantor Fitzgerald
Stoke Therapeutics, Inc. stock logo
STOK FY2025 EPS Forecast Lowered by Cantor Fitzgerald
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Stoke Therapeutics in a report released on Thursday, June 12th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post
Stoke Therapeutics: Impressive Pipeline And Big Backers
Stoke Therapeutics, Inc. stock logo
Assenagon Asset Management S.A. Sells 391,322 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)
Assenagon Asset Management S.A. lowered its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 29.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 959,603 shares of the co
Stoke Therapeutics, Inc. stock logo
Cantor Fitzgerald Predicts STOK FY2026 Earnings
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Stoke Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post ea
Stoke Therapeutics, Inc. stock logo
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 123.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 95,505
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Two Sigma Investments LP
Two Sigma Investments LP trimmed its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 53.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,950 shares of the company's stock after selling 62,728 shares
Stoke Therapeutics, Inc. stock logo
Jane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)
Jane Street Group LLC cut its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 96.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,977 shares of the company's stock after selling 318,465 shares
Stoke Therapeutics, Inc. stock logo
Millennium Management LLC Increases Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Millennium Management LLC raised its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 417.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 76,829 shares of the company's stock after pu
Stoke Therapeutics, Inc. stock logo
Barry Ticho Sells 1,745 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 1,745 shares of Stoke Therapeutics stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $10.00, for a total value of $17,450.00. Following the transaction, the insider now owns 32,253 shares in the company, valued at $322,530. This represents a 5.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 6,471 Shares
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 6,471 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the completion of the transaction, the insider now owns 25,782 shares in the company, valued at $258,593.46. The trade was a 20.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have earned a consensus rating of "Buy" from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have given a strong buy recomme
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (NASDAQ:STOK) Trading 10.3% Higher - Here's Why
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 10.3% - Time to Buy?
Stoke Therapeutics, Inc. stock logo
BNP Paribas Financial Markets Trims Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)
BNP Paribas Financial Markets trimmed its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 94.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,422 shares of the co
Stoke Therapeutics, Inc. stock logo
Voloridge Investment Management LLC Sells 36,261 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)
Voloridge Investment Management LLC lessened its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 29.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 86,888 shares of the company's stock after selling 36,
Stoke Therapeutics, Inc. stock logo
D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)
D. E. Shaw & Co. Inc. decreased its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 83.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,043 shares of the company's
Stoke Therapeutics, Inc. stock logo
Toronto Dominion Bank Invests $35 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Toronto Dominion Bank acquired a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,173,258 shares of the company's stock, valued at approxi
Stoke Therapeutics, Inc. stock logo
Deutsche Bank AG Reduces Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Deutsche Bank AG decreased its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 24.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 350,614 shares of the company's stock after selling
Stoke Therapeutics, Inc. stock logo
Toronto Dominion Bank Acquires New Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Toronto Dominion Bank bought a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 3,173,258 shares of the company's stoc
Stoke Therapeutics, Inc. stock logo
Tang Capital Management LLC Buys Shares of 300,000 Stoke Therapeutics, Inc. (NASDAQ:STOK)
Tang Capital Management LLC acquired a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 300,000 shares of the company's stock, valued at approximately $3,309,000. Tang Capital
Stoke Therapeutics, Inc. stock logo
Chardan Capital Has Strong Forecast for STOK FY2025 Earnings
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Investment analysts at Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a report issued on Wednesday, May 14th. Chardan Capital analyst R. Li now expects that the company will earn $0.
Stoke Therapeutics, Inc. stock logo
RTW Investments LP Has $56.51 Million Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)
RTW Investments LP increased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 10.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,123,525 shares of the company's stock
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Cantor Fitzgerald
Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday.
Stoke Therapeutics, Inc. stock logo
MPM Bioimpact LLC Has $7.57 Million Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)
MPM Bioimpact LLC lifted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 43.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 685,826 shares of the company's stock after
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up Following Earnings Beat
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up on Better-Than-Expected Earnings
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP increased its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 103.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 538,900 shares of the company's stock after purchasing an addi
Stoke Therapeutics, Inc. stock logo
Granahan Investment Management LLC Trims Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Granahan Investment Management LLC cut its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 12.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 567,689 shares of the company's stock after selling 77,281
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Brokerages
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has received a consensus rating of "Buy" from the seven brokerages that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy re
Stoke Therapeutics, Inc. stock logo
DAFNA Capital Management LLC Has $1.89 Million Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)
DAFNA Capital Management LLC trimmed its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 17.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 171,097 shares of the company's stock after
Stoke Therapeutics, Inc. stock logo
Baker BROS. Advisors LP Increases Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Baker BROS. Advisors LP boosted its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 6.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,633,838 shares of the company's stock after bu
Stoke Therapeutics, Inc. stock logo
291,795 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Acquired by Schonfeld Strategic Advisors LLC
Schonfeld Strategic Advisors LLC acquired a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 291,795 shares of the company's stock, valued at approximately $3,218,000. Schonfeld Strategic
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.4% - Here's Why
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.4% - Time to Sell?
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (STOK) Projected to Post Quarterly Earnings on Monday
Stoke Therapeutics (NASDAQ:STOK) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-stoke-therapeutics-inc-stock/)
Stoke Therapeutics, Inc. stock logo
Renaissance Technologies LLC Invests $1.42 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Renaissance Technologies LLC bought a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 129,043 shares of the company's stock, valued at approxim
Stoke Therapeutics, Inc. stock logo
Marshall Wace LLP Sells 719,301 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)
Marshall Wace LLP decreased its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 43.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 951,432 shares of the company's stock after selling 719
Stoke Therapeutics, Inc. stock logo
FY2029 Earnings Estimate for STOK Issued By Leerink Partnrs
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at Leerink Partnrs upped their FY2029 earnings per share (EPS) estimates for Stoke Therapeutics in a research report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn $0.60 per
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Buy" by Analysts
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been assigned an average rating of "Buy" from the eight brokerages that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. T
Stoke Therapeutics, Inc. stock logo
Trexquant Investment LP Sells 58,718 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)
Trexquant Investment LP lowered its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 36.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 103,031 shares of the company's stock after selling 58,718 shar
Stoke Therapeutics, Inc. stock logo
314,800 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Acquired by Norges Bank
Norges Bank bought a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 314,800 shares of the company's stock, valued at approximately $3,47
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday.
Needham Keeps Their Buy Rating on Stoke Therapeutics (STOK)
Get Stoke Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.

STOK Media Mentions By Week

STOK Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

STOK
News Sentiment

0.34

0.69

Average
Medical
News Sentiment

STOK News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

STOK Articles
This Week

8

5

STOK Articles
Average Week

Get Stoke Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:STOK) was last updated on 6/19/2025 by MarketBeat.com Staff
From Our Partners